5 not yet recruiting, 3 recruiting, 1 active not recruiting, 1 unknown. 3 Not applicable, 3 Phase 2, 2 Phase 3, 1 Early Phase 1, 1 Phase 1.
Follow Cachexia-Anorexia Syndrome: new trials by email Literature Review of Cachexia-Anorexia Syndrome trials Research Report on Cachexia-Anorexia Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Clinical Study Evaluating the Efficacy and Safety of SXRN Injection in Patients With Cancer Cachexia SXRN Injection, Placebo - Cachexia-Anorexia Syndrome, Cachexia; Cancer | Phase 2 | Not yet recruiting | Jiangsu Guiqiong Pharmaceutical Co., Ltd. | 96 | 2026-12-01 | 2026-10-26 |
| The Aim of the Study is to Decipher the Alterations in Signalling Pathways of Skeletal Muscle Stem Cells (Satellite Cells (SCs)) in Individuals With COPD, as Well as to Examine the Effect of Exercise Training on SCs. Exercise training - COPD (Chronic Obstructive Pulmonary Disease), Sarcopenia in Elderly | Not applicable | Not yet recruiting | University Hospital, Bordeaux | 26 | 2026-11-15 | 2026-11-06 |
| Master Protocol for the Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC Rilogrotug, Placebo - Cachexia; Cancer, Cachexia | Phase 2 / Phase 3 | Not yet recruiting | AVEO Pharmaceuticals, Inc. | 950 | 2026-11-01 | 2026-10-28 |
| Feasibility Study for Repurposing RET Inhibitors Selpercatinib, Strength Assessment - Cachexia-Anorexia Syndrome | Early Phase 1 | Not yet recruiting | University of Oklahoma | 7 | 2026-02-26 | 2026-01-15 |
| A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of SXRN Injection in Patients With Cancer Cachexia SXRN Injection - Cachexia-Anorexia Syndrome, Solid Tumor Malignancies | Phase 1 | Recruiting | Jiangsu Nutai Biologics Co., Ltd | 54 | 2025-11-17 | 2025-12-08 |
| Nano-crystalline Megestrol Acetate for Anorexia-Cachexia Syndrome in Advanced Lung Cancer Nano-crystalline Megestrol Acetate Oral Suspension, Nano-crystalline Megestrol Acetate Oral Suspension placebo - Lung Cancer, Cachexia-Anorexia Syndrome | Phase 2 | Not yet recruiting | Guangzhou Institute of Respiratory Disease | 116 | 2025-10-10 | 2025-07-29 |
| Olanzapine in the Prevention and Treatment of Anorexia-Cachexia Syndrome in Patients Receiving Neoadjuvant/Preoperative Chemotherapy OLANZapine 2.5 MG - Oncology Patients Receiving Chemotherapy, Cachexia-Anorexia Syndrome | Phase 3 | Recruiting | Blokhin's Russian Cancer Research Center | 100 | 2025-03-28 | 2026-06-08 |
| Neurobehavioural and Cognitive Changes in Cancer Cachexia (CANCOG) MRI/ Functional MRI, Self-reported questionnaires, Computer based tasks - Cancer, Cachexia | Recruiting | University of Cambridge | 50 | 2024-02-15 | 2024-07-17 | |
| Exercise Intervention for Patients With Cancer Cachexia: Effects of a 12-week Program and One-year Follow-up. Exercise Intervention - Cachexia-Anorexia Syndrome | Not applicable | Unknown | Peyrachon Romane | 31 | 2024-01-01 | 2024-03-21 |
| Self-Management Support for Lung Cancer Patients With Cachexia Self-management support nutrition and exercise intervention - Cachexia-Anorexia Syndrome, Lung Neoplasm Malignant | Not applicable | Active not recruiting | Changhua Christian Hospital | 104 | 2023-01-20 | 2026-05-13 |
Neoplasms (5) · Cachexia (4) · Anorexia (2) · Lung Neoplasms (2) · Motor Activity (2) · Weight Loss (2) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Muscular Atrophy (1) · Pulmonary Disease, Chronic Obstructive (1) · Sarcopenia (1)
Pathological Conditions, Signs and Symptoms (5) · Signs and Symptoms (5) · Body Weight (4) · Body Weight Changes (4) · Lung Diseases (4) · Respiratory Tract Diseases (4) · Thinness (4) · Neoplasms by Site (3) · Respiratory Tract Neoplasms (3) · Thoracic Neoplasms (3) · Behavior (2) · Neoplasms (2) · Signs and Symptoms, Digestive (2) · Weight Loss (2) · Atrophy (1)
Exercise (1) · Magnetic Resonance Spectroscopy (1) · Olanzapine (1) · selpercatinib (1)
AVEO Pharmaceuticals, Inc. (1) · Blokhin's Russian Cancer Research Center (1) · Changhua Christian Hospital (1) · Guangzhou Institute of Respiratory Disease (1) · Jiangsu Guiqiong Pharmaceutical Co., Ltd. (1) · Jiangsu Nutai Biologics Co., Ltd (1) · Peyrachon Romane (1) · University Hospital, Bordeaux (1) · University of Cambridge (1) · University of Oklahoma (1)
China (2) · France (2) · Russia (1) · Taiwan (1) · United Kingdom (1) · United States (1)
Anthony P Coll (1) · Li Chun Chang, Master (1) · Nirmal Choradia, MD (1) · Romane Peyrachon, MhD (1) · Tsae Jyy Wang, PhD (1)
PMID 27637832, PMID 30741408, PMID 31626055, PMID 32119883, PMID 33946039, PMID 40413464